A clinical study for the therapeutic effect of arotinib on patients with stage III primary liver cancer after interventional therapy

Abstract

Abstract: Objective To investigate the efficacy of transcatheter arterial chemoembolization (TACE) combined with arotinib on the treatment of stage III primary liver cancer.Methods 205 patients with stage III liver cancer who were treated in Hengshui Third People's Hospital from January 2020 to January 2023 were divided into a control group (n=103) and an observation group (n=102). After TACE therapy, patients in the observation group were administrated with arotinib and evaluated for the clinical efficacy.Results One month after surgery, the Karnofsky score was (79.5±8.0) in the observation group, which was higher than that of (75.3±8.3) in the control group (P<0.05). After treatment, the serum levels of alpha fetoprotein (AFP) and carcinoembryonic antigen (CEA) in the observation group were (558.82±49.87)ng/L and (33.89±5.45)ng/mL, respectively, which were significantly lower than those in the control group (P<0.05). Serum vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and γ-Glutamyle transferase (GGT) in the observation group were significantly lower than those in the control group (P<0.05); The disease control rate in the control group was 69.90%, while the disease control rate in the observation group was 88.23%, which was superior to the control group (χ²=11.959, P=0.008); There was no significant difference in adverse reactions between the control group and the observation group (P>0.05).Conclusion TACE combined with arotinib in the treatment of advanced liver cancer patients significantly improve clinical efficacy without increasing adverse reactions.

Key words: Primary liver cancer, Transcatheter arterial chemoembolization, Arotinib, Clinical efficacy

WANG Chun-hong, FENG Wei-wei, ZHANG Jing, SI Chen-fei. A clinical study for the therapeutic effect of arotinib on patients with stage III primary liver cancer after interventional therapy[J]. Chinese Hepatolgy, 2023, 28(8): 928-931.

References

[1] Ikeda K. Recent advances in medical management of hepatocellular carcinoma. Hepatol Res,2019,49:14-32.
[2] Guo W,Chen S,Wu Z,et al.Efficacy and safety of transarterial chemoembolization combined with anlotinib for unresectable hepatocellular carcinoma:a retrospective study.Technol Cancer Res Treat,2020,19:15-33.
[3] Liu S,Qin T,Liu Z,et al.Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.Cell Death Dis,2020,11(5):309-318.
[4] Barz M,Gerhardt J,Bette S,et al.Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale-a bicentric retrospective study.BMC Neurol,2021,21:446-446.
[5] Sen A,Ryan PB,Goldstein A,et al.Correlating eligibility criteria generalizability and adverse events using big data for patients and clinical trials.Ann N Y Acad Sci,2017,1387:34-43.
[6] Chiu SH,Chang PY,Shih YL,et al.Efficacy and safety of supplemental transarterial chemoembolization through extrahepatic collateral arteries with drug-eluting beads:treatment for unresectable hepatocellular carcinoma.Drug Des Devel Ther,2020,14:5029-5041.
[7] Bucalau AM,Tancredi I,Verset G.In the Era of systemic therapy for hepatocellular carcinoma is transarterial chemoembolization still a card to play?Cancers,2021,13:5129-5138.
[8] Wang G,Sun M,Jiang Y,et al. Anlotinib,a novel small molecular tyrosine kinase inhibitor,suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.Int J Cancer,2019.,145:979-993.
[9] Song F,Hu B,Cheng JW,et al. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.Cell Death Dis,2020,11:573-573.
[10] Xie C,Wan X,Quan H,et al. Preclinical characterization of anlotinib,a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.Cancer Sci,2018,109:1207-1219.
[11] 陈思攀,杨耀博,焦阳,等.经导管动脉栓塞术联合小干扰核糖核酸治疗肝癌疗效及对兔缺氧诱导因子-1、血管内皮生长因子的影响.陕西医学杂志,2021,50(5):534-537,549.
[12] 文艺,张艳,龚星云,等.肝动脉灌注化疗栓塞后联合安罗替尼治疗中晚期肝癌临床疗效观察.中国冶金工业医学杂志,2021,38(6):627-628.
[13] Zhang A,Liu B,Xu D,et al.Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: a case report.Med,2019.98:184-195.
[14] 郭稳稳, 程昌盛, 吴燕,等. 安罗替尼联合肝动脉化疗栓塞术治疗晚期肝癌的疗效及对血清肿瘤相关因子的影响. 川北医学院学报, 2022(7):037.

[1]	LI Jiao-jiao, ZHAO Yong-chang, WU Jun-xia. The T lymphocyte and NK cell levels in patients with malignant pleural effusion after radical resection of primary hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(8): 924-927.
[2]	XU Zheng-ju, LIU Hui-guo, YAN Yan-yan, YE Qiao-xia, ZHANG Xiao-man, HUANG Jin-fa, LI Yong-fei, WU Jin-piao. Effect of microwave ablation on serum levels of Golgi protein 73 and alpha fetoprotein in patients with primary liver cancer [J]. Chinese Hepatolgy, 2023, 28(5): 554-558.
[3]	ZHU Ye-chen, GENG Cheng-jun, YIN Hui-kang, LI Ya-nan, FENG Quan-ye. The application of three-dimensional reconstruction in the evaluation of vascular system of primary liver cancer before TACE intervention [J]. Chinese Hepatolgy, 2023, 28(5): 559-563.
[4]	QIN Xiao-ping, ZHANG Jing, AI Ping. The expression of TREM-1, sCD163 and sB7-H3 in patients with primary liver cancer [J]. Chinese Hepatolgy, 2023, 28(4): 461-464.
[5]	GUO Dan-dan, ZHANG Ying-hua, GAO Wen-feng, SHENG Shou-peng, ZHANG Yong-hong. Clinical features of primary liver cancer associated with Wilson's disease [J]. Chinese Hepatolgy, 2023, 28(3): 290-292.
[6]	LIU Er-li, LI Bo-qun, HUANG Ying-ting, CUI Hao, WANG Xiao-jun, ZHANG Hong-ying. Cost-effectiveness comparison of four treatment strategies for primary liver cancer [J]. Chinese Hepatolgy, 2023, 28(2): 193-199.
[7]	WANG Yang, XU Zhen, WANG Zheng, PAN Zhi. Comparison of clinical efficacy of ERCP and LBEPS combined with LC in the treatment of gallbladder complicated with common bile duct stones [J]. Chinese Hepatolgy, 2023, 28(1): 108-111.
[8]	CHAI Xiao-zhe, ZHU Xia-feng, WANG Shao-feng, LUP Cheng-lin. Predictive value of albumin-bilirubin score in combination with blood ammonia detection for hepatic encephalopathy after resection of primary liver cancer [J]. Chinese Hepatolgy, 2022, 27(9): 994-998.
[9]	MA Jun-wei, LIU Ji-qiang, SONG Ran. The guiding value of intravoxel incoherent motion diffusion-weighted imaging in the curative effect of argon-helium knife cryotherapy on primary liver cancer [J]. Chinese Hepatolgy, 2022, 27(7): 778-781.
[10]	ZHOU Cheng-xiang, LIU Ya-bin, SU Hong, JIANG Yi-xiang, LIN Hai-yan. The evaluation value of contrast-enhanced ultrasound on blood supply in patients with primary liver cancer after microwave ablation [J]. Chinese Hepatolgy, 2022, 27(6): 637-639.
[11]	LI Jian, CHENG Jing-hua, TIAN Jie, LI You-xuan, LIAO De-zhong, XU Jing. A comparative analysis between the clinical features of hepatitis B virus-related and nonvirus-related primary liver cancers [J]. Chinese Hepatolgy, 2022, 27(4): 460-465.
[12]	LI Long, ZHENG Zhen-dong, DU Cheng, LIU Bo-na. Efficacy of bevacizumab combined with TACE in the treatment of advanced hepatocellular carcinoma [J]. Chinese Hepatolgy, 2022, 27(3): 281-283.
[13]	WANG Bin, QI Xian-wei, ZHANG Xian-liang. The value of US-CT/MRI fusion imaging technology in precision radiofrequency therapy of primary liver cancer [J]. Chinese Hepatolgy, 2022, 27(2): 199-202.
[14]	JI Qin, SHEN Yu-chneg, SHAO Chun-yan. The value of PIVKA Ⅱ and serum AFP - L3 levels for evaluating the prognosis of primary liver cancer after TACE Therapy [J]. Chinese Hepatolgy, 2022, 27(2): 210-212.
[15]	HUANG Shi-wen, ZENG Mei-hui. Ultrasonographic characteristics of primary liver cancer patients with KRAS gene mutation and the correlation between KRAS gene mutation and lymph node metastasis [J]. Chinese Hepatolgy, 2022, 27(12): 1280-1283.